Extremity Care LLC

Biotechnology Company

Based in PA

Share:𝕏LinkedInFacebook
🤖

AI Overview

With $260K in lobbying spend across 4 quarterly filings, Extremity Care LLC is an active lobbying client. Their lobbying covers 1 issue area.

$260K
Total Spend
1
Years Active
1
Firms Hired
5
Lobbyists Deployed
1
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2024$260K

Issues Lobbied

MED

Lobbying Firms

Ballard Partners

Lobbyists

Daniel McfaulMichael LarosaTola ThompsonBrian BallardGerald John O'hanlon

Government Agencies Targeted

These are the government entities that Extremity Care LLC disclosed contacting in their lobbying filings.

Centers For Medicare and Medicaid Services (CMS)Health & Human Services, Dept of (HHS)HOUSE OF REPRESENTATIVESSENATE
View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: MED

Promoting the advancement of healthcare technology.

Related Analysis

📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?

Related Investigations

Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.

Similar Clients

Drexel University
$3.4M total spend
University of Pennsylvania Perelman School of Medicine
$1.0M total spend
Tiger Biosciences
$860K total spend
Amerihealth Caritas
$720K total spend
Mural Health
$500K total spend

Explore More

← All Clients⚖️ Compare Clients💵 ROI Calculator🔍 Investigations📖 How Lobbying Works🕸️ Network Analysis🏛️ Agency Pressure

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.